40 Hz Steady-State Response in Human Auditory Cortex Is Shaped by Gabaergic Neuronal Inhibition.
Alessandro TosoAnnika P WermuthAyelet AraziAnke BraunTineke Grent-'t JongPeter J UhlhaasTobias Hinrich DonnerPublished in: The Journal of neuroscience : the official journal of the Society for Neuroscience (2024)
The 40 Hz auditory steady-state response (ASSR), an oscillatory brain response to periodically modulated auditory stimuli, is a promising, noninvasive physiological biomarker for schizophrenia and related neuropsychiatric disorders. The 40 Hz ASSR might be amplified by synaptic interactions in cortical circuits, which are, in turn, disturbed in neuropsychiatric disorders. Here, we tested whether the 40 Hz ASSR in the human auditory cortex depends on two key synaptic components of neuronal interactions within cortical circuits: excitation via N-methyl-aspartate glutamate (NMDA) receptors and inhibition via gamma-amino-butyric acid (GABA) receptors. We combined magnetoencephalography (MEG) recordings with placebo-controlled, low-dose pharmacological interventions in the same healthy human participants (13 males, 7 females). All participants exhibited a robust 40 Hz ASSR in auditory cortices, especially in the right hemisphere, under a placebo. The GABA A receptor-agonist lorazepam increased the amplitude of the 40 Hz ASSR, while no effect was detectable under the NMDA blocker memantine. Our findings indicate that the 40 Hz ASSR in the auditory cortex involves synaptic (and likely intracortical) inhibition via the GABA A receptor, thus highlighting its utility as a mechanistic signature of cortical circuit dysfunctions involving GABAergic inhibition.
Keyphrases
- working memory
- endothelial cells
- hearing loss
- low dose
- induced pluripotent stem cells
- pluripotent stem cells
- placebo controlled
- randomized controlled trial
- squamous cell carcinoma
- bipolar disorder
- clinical trial
- white matter
- high dose
- radiation therapy
- study protocol
- double blind
- multiple sclerosis
- angiotensin ii
- angiotensin converting enzyme
- rectal cancer
- brain injury
- locally advanced
- living cells
- single molecule
- drug induced
- phase ii study